Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences

REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences.

Conference Details:

BTIG 3rd Annual Ophthalmology Day

Format: Fireside Chat
Date: Monday, November 27, 2023
Time: 4:30 p.m. ET
Location: Virtual

Ashvattha’s Co-Founder, President, and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings. If you are interested in a meeting, please contact your BTIG representative.

Ophthalmology Innovation Summit (OIS) XIII

Format: Corporate Presentation
Date: Friday, December 1, 2023
Time: 1:01 p.m. PT
Location: Omni San Diego Hotel

About Ashvattha Therapeutics
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. For more information, visit: www.avttx.com

Media Contact
Gloria Gasaatura
LifeSci Communications
ggasaatura@lifescicomms.com
646-970-4688

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.